Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Oncogenic Ras proteins require farnesyl modification for cell transformation.
• Farnesyltransferase enzyme catalyzes the attachment of farnesyl residues to specific cysteine residues near the C-terminus of target proteins.
• The enzyme recognizes a CAAX tetrapeptide motif, where C is cysteine, A is an aliphatic amino acid, and X is methionine or serine.

Purpose of the Study:

• To develop potent inhibitors of farnesyltransferase.
• To investigate the efficacy of benzodiazepine-based peptidomimetics as Ras inhibitors.
• To evaluate the therapeutic potential of these inhibitors in cancer treatment.

Main Methods:

• Design and synthesis of benzodiazepine-based peptidomimetics mimicking peptide turns.
• In vitro enzymatic assays to determine farnesyltransferase inhibition (IC50).
• Cell-based assays to assess farnesyl attachment to Ras and other proteins, and to evaluate effects on cell growth.

Main Results:

• Benzodiazepine peptidomimetics demonstrated potent inhibition of farnesyltransferase (IC50 < 1 nM).
• These peptidomimetics successfully entered cells and inhibited farnesylation of Ras, nuclear lamins, and other proteins.
• Micromolar concentrations of the inhibitors reverted the malignant phenotype of Ras-transformed cells, restoring normal growth patterns.

Conclusions:

• Benzodiazepine peptidomimetics are effective inhibitors of farnesyltransferase and Ras protein modification.
• These compounds show promise for treating cancers driven by oncogenic Ras proteins, including colon, lung, and pancreatic cancers.
• The cell-permeable nature and potent inhibitory activity of these peptidomimetics make them valuable candidates for drug development.